Summary by Futu AI
China Biopharmaceuticals Limited announced on 29 April 2024 that, pursuant to the amendments to the listing rules of the Stock Exchange of Hong Kong Stock Exchange Limited, the Company will use a new electronic means of issuing corporate communications to non-registered shareholders from 31 December 2023. The Chinese and English versions of all future corporate communications will be available on the company's and exchange's websites, replacing printed mailings. The Company will send a notice of publication of a version of the Company's newsletter by email or post, provided that the shareholder's bank, broker, custodian, agent or Hong Kong Central Clearing (Agent) Limited has provided the shareholder's email or postal address. Shareholders who wish to continue receiving printed copies may complete the application form and submit a request to the Company's Share Registrar by 31 December 2025. THE COMPANY ALSO REMINDS SHAREHOLDERS THAT THE COMPANY'S ANNUAL REPORTS AND RELATED CIRCULARS ARE AVAILABLE ON THE WEBSITE.